The focus of the partnership has shifted to whether solutions targeting the microbiome can deliver benefits alongside GLP-1-based medicines<\/p>\n
(Reuters) \u2014 Danish biosolutions maker\u00a0Novonesis\u00a0expects\u00a0results\u00a0in the second half of\u00a02027\u00a0from\u00a0research with Novo Nordisk into whether microbiome\u00a0supplements could provide additional benefits alongside GLP-1\u00a0weight-loss\u00a0drugs, its chief executive told Reuters.<\/p>\n
The companies announced the partnership last year to explore how the gut microbiome could improve metabolic health and to develop and test synbiotic food\u00a0supplements.<\/p>\n
The focus has since shifted to whether solutions targeting the microbiome can deliver benefits alongside GLP-1-based medicines, a Novo Nordisk spokesperson said in an emailed statement.<\/p>\n
Novonesis\u00a0CEO Ester Baiget said people taking GLP-1 medicines would also take \u201ca combination of synbiotics, probiotics and prebiotics\u201d, with\u00a0results\u00a0from\u00a0the research expected in the second half of\u00a02027.<\/p>\n
When announcing the collaboration, the companies said they planned to\u00a0study\u00a0the\u00a0supplements\u2019 effects on measures including blood glucose and cholesterol, as well as changes in the gut microbiome and related biomarkers.<\/p>\n
The work brings together Novo Nordisk, maker of obesity\u00a0drug\u00a0Wegovy, and\u00a0Novonesis\u2019 expertise in probiotics and the human microbiome, as companies seek to develop products and services tailored to users of\u00a0weight-loss\u00a0drugs.<\/p>\n
Novo Nordisk, Eli Lilly and other\u00a0drugmakers are racing to capture a share of the booming obesity market, and growing use of GLP-1 medicines is creating opportunities for food, nutrition and\u00a0supplement\u00a0companies targeting patients\u2019 changing dietary needs.<\/p>\n
Nestle is developing products aimed at\u00a0weight-loss\u00a0drug\u00a0users, while dairy companies and food manufacturers are investing to meet rising demand for protein-rich products.<\/p>\n
Novonesis, formed through the merger of Novozymes and Chr. Hansen, supplies enzymes and microorganisms. Its Human Health business includes probiotics, human milk oligosaccharides and other nutrition products.<\/p>\n
Baiget declined to say whether\u00a0Novonesis\u00a0could pursue similar collaborations with other obesity-drug\u00a0makers.<\/p>\n
(Reporting by Vera Dvorakova and Jesus Calero in Gdansk; editing by Matt Scuffham)<\/p>\n
More from ATN<\/p>\n","protected":false},"excerpt":{"rendered":"The focus of the partnership has shifted to whether solutions targeting the microbiome can deliver benefits alongside GLP-1-based…\n","protected":false},"author":2,"featured_media":149543,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[5966,272,7680,280],"class_list":["post-149542","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-glp-1s","tag-novo-nordisk","tag-study","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117129129901450123","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/149542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=149542"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/149542\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/149543"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=149542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=149542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=149542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}